Skip to main content
Erschienen in: Medical Oncology 1/2009

01.03.2009 | Original Paper

Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin’s lymphoma in a patient with pituitary acromegaly

verfasst von: A. Taslipinar, E. Bolu, L. Kebapcilar, M. Sahin, G. Uckaya, M. Kutlu

Erschienen in: Medical Oncology | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

The effects of growth hormone are mediated in part by stimulating the production of insulin-like growth factor-1. Insulin-like growth factor-1 has significant effects on cell proliferation and differentiation, it is a potent mitogen, and it is a powerful inhibitor of programmed cell death (apoptosis). Insulin-like growth factor-1 also has a well-established role in the transformation of normal cells to malignant cells. Case reports on a possible association between elevated growth hormone and cancer risk in a variety of patient groups have been published. Here, we describe clinical and laboratory findings for a patient with acromegaly who first developed thyroid cancer, and then, in the follow up period, probably due to poorly controlled insulin-like growth factor-1 levels, developed a large cell non-Hodgkin’s lymphoma. A search revealed that a case with these peculiarities had not previously been reported.
Literatur
3.
Zurück zum Zitat Prisco M, Romano G, Peruzzi F, Valentinis P, Baserga R. Insulin and IGF-I receptors signaling in protection from apoptosis. Horm Metab Res. 1999;31:80–9.PubMedCrossRef Prisco M, Romano G, Peruzzi F, Valentinis P, Baserga R. Insulin and IGF-I receptors signaling in protection from apoptosis. Horm Metab Res. 1999;31:80–9.PubMedCrossRef
5.
Zurück zum Zitat Alves RH, Vaisman M, Brasil RR, Gadelha MR. Acromegaly and non-Hodgkin’s lymphoma. Endocr Pract. 1998;4:279–81.PubMed Alves RH, Vaisman M, Brasil RR, Gadelha MR. Acromegaly and non-Hodgkin’s lymphoma. Endocr Pract. 1998;4:279–81.PubMed
6.
Zurück zum Zitat Busygina V, Bale AE. Multiple endocrine neoplasia type 1 (MEN1) as a cancer predisposition syndrome: clues into the mechanisms of MEN1-related carcinogenesis. Yale J Biol Med. 2006;79:105–14.PubMed Busygina V, Bale AE. Multiple endocrine neoplasia type 1 (MEN1) as a cancer predisposition syndrome: clues into the mechanisms of MEN1-related carcinogenesis. Yale J Biol Med. 2006;79:105–14.PubMed
9.
Zurück zum Zitat AACE Acromegaly Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract. 2004;10:213–25. AACE Acromegaly Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocr Pract. 2004;10:213–25.
10.
Zurück zum Zitat Ezzat S, Melmed S. Clinical review 18: are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab. 1991;72:245–9.PubMed Ezzat S, Melmed S. Clinical review 18: are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab. 1991;72:245–9.PubMed
12.
Zurück zum Zitat Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med. 1970;39:1–16.PubMed Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med. 1970;39:1–16.PubMed
13.
Zurück zum Zitat Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223:327–35.PubMed Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. A study of 166 cases diagnosed between 1955 and 1984. Acta Med Scand. 1988;223:327–35.PubMed
14.
Zurück zum Zitat Etxabe J, Gaztambide P, Latorre P, Vazquez JA. Acromegaly: an epidemiological study. J Endocrinol Invest. 1993;16:181–7.PubMed Etxabe J, Gaztambide P, Latorre P, Vazquez JA. Acromegaly: an epidemiological study. J Endocrinol Invest. 1993;16:181–7.PubMed
17.
Zurück zum Zitat Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998;83:2730–4. doi:10.1210/jc.83.8.2730.PubMedCrossRef Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998;83:2730–4. doi:10.​1210/​jc.​83.​8.​2730.PubMedCrossRef
21.
Zurück zum Zitat Kasagi K, et al. Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland. Thyroid. 1999;9:791–6.PubMedCrossRef Kasagi K, et al. Goiter associated with acromegaly: sonographic and scintigraphic findings of the thyroid gland. Thyroid. 1999;9:791–6.PubMedCrossRef
22.
Zurück zum Zitat Cannavò S, et al. Goiter and impairment of thyroid function in acromegalic patients: basal evaluation and follow-up. Horm Metab Res. 2000;32:190–5.PubMedCrossRef Cannavò S, et al. Goiter and impairment of thyroid function in acromegalic patients: basal evaluation and follow-up. Horm Metab Res. 2000;32:190–5.PubMedCrossRef
23.
Zurück zum Zitat Gasperi M, et al. Acromegaly Study Group of the Italian Society of Endocrinology. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest. 2002;25:240–5.PubMed Gasperi M, et al. Acromegaly Study Group of the Italian Society of Endocrinology. Prevalence of thyroid diseases in patients with acromegaly: results of an Italian multi-center study. J Endocrinol Invest. 2002;25:240–5.PubMed
25.
Zurück zum Zitat Cats A, et al. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res. 1996;56:523–6.PubMed Cats A, et al. Increased epithelial cell proliferation in the colon of patients with acromegaly. Cancer Res. 1996;56:523–6.PubMed
28.
Zurück zum Zitat Roger P, Taton M, Van Sande J, Dumont JE. Mitogenic effects of thyrotropin and adenosine 3′,5′-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab. 1988;66:1158–65.PubMedCrossRef Roger P, Taton M, Van Sande J, Dumont JE. Mitogenic effects of thyrotropin and adenosine 3′,5′-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab. 1988;66:1158–65.PubMedCrossRef
29.
Zurück zum Zitat Minuto F, et al. Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I-binding protein content in human thyroid tissue. J Clin Endocrinol Metab. 1989;68:621–6.PubMed Minuto F, et al. Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I-binding protein content in human thyroid tissue. J Clin Endocrinol Metab. 1989;68:621–6.PubMed
31.
Zurück zum Zitat Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol. 2005;152:569–74. doi:10.1530/eje.1.01888.PubMedCrossRef Selvarajah D, Webster J, Ross R, Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol. 2005;152:569–74. doi:10.​1530/​eje.​1.​01888.PubMedCrossRef
33.
Zurück zum Zitat Colao A, et al. Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest. 2007;30:693–9.PubMed Colao A, et al. Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest. 2007;30:693–9.PubMed
37.
Metadaten
Titel
Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin’s lymphoma in a patient with pituitary acromegaly
verfasst von
A. Taslipinar
E. Bolu
L. Kebapcilar
M. Sahin
G. Uckaya
M. Kutlu
Publikationsdatum
01.03.2009
Verlag
Humana Press Inc
Erschienen in
Medical Oncology / Ausgabe 1/2009
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-008-9084-9

Weitere Artikel der Ausgabe 1/2009

Medical Oncology 1/2009 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.